ReviewPLoS neglected tropical diseases2025
Guaroa virus, a forgotten Latin American orthobunyavirus: A narrative review.
Review in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Guaroa virus (GROV) is a neglected arthropod-borne orthobunyavirus, primarily endemic to parts of Central and South America. Its epidemiological and clinical impact remains unclear due to limited research and underreporting. It has been sporadically associated with mild febrile illness in humans. GROV is thought to be transmitted by Anopheles spp. mosquitoes, but its natural reservoir hosts remain unknown. Clinically, GROV infection is characterized by fever, headache, malaise, chills, and myalgia. Co-infections with other pathogens related to febrile illnesses can occur in endemic areas. Diagnosis relies on viral isolation and reverse transcription polymerase chain reaction (RT-PCR) during the acute phase and serological testing in later stages. Although not directly oncogenic, GROV has been shown in experimental murine models to enhance the tumorigenic potential of certain oncogenic viruses; however, the underlying mechanisms remain unclear, and no evidence of this effect exists in humans. Risk factors include male gender, outdoor occupations, and living near mosquito habitats. Preventive measures focus on reducing vector contact. Future research is urgently needed to clarify GROV's ecology and importance, including the identification of natural reservoirs, the role of Anopheles mosquitoes as competent vectors, and its true public health burden, particularly in rural and low-resource areas where diagnostic capacity is limited and multiple febrile illnesses co-circulate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.